NewslettersDermal Cell NewsImmune Regulation NewsAslan Sells Japanese Rights to Would-Be Dupixent Rival for $12MBy Laurisa Dohm - June 26, 2023057Zenyaku Kogyo is lining up a challenge to Sanofi and Regeneron’s blockbuster Dupixent in Japan, paying Aslan Pharmaceuticals $12 million upfront for local rights to a midphase eczema drug candidate.[Fierce Biotech]Press Release